Corium International, Inc. (CORI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Corium International, Inc. (CORI) with AI Score 44/100 (Weak). Corium International, Inc. is a biopharmaceutical company focused on the development, manufacture, and commercialization of transdermal drug delivery systems. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Corium International, Inc. (CORI) Healthcare & Pipeline Overview
Corium International, Inc. specializes in transdermal drug delivery systems, offering innovative solutions for improved patient compliance and drug efficacy. With a focus on developing, manufacturing, and commercializing advanced delivery technologies, Corium operates within the competitive pharmaceutical landscape, facing challenges in profitability and market penetration.
Investment Thesis
Corium International, Inc. presents a complex investment case. The company's focus on transdermal drug delivery systems offers potential for growth in a market increasingly favoring patient-friendly drug delivery methods. However, the company's negative P/E ratio of -7.71 and a profit margin of -150.0% raise concerns about its financial stability and profitability. Upcoming catalysts include potential regulatory approvals for new transdermal products and expansion of existing partnerships. Successful commercialization of new products and improved cost management are key value drivers. Potential risks include competition from established pharmaceutical companies, regulatory hurdles, and the need for significant capital investment in research and development.
Based on FMP financials and quantitative analysis
Key Highlights
- Specializes in transdermal drug delivery systems, offering innovative solutions for improved patient compliance.
- Gross margin of 18.8% indicates potential for improvement in operational efficiency.
- Negative P/E ratio of -7.71 reflects current challenges in achieving profitability.
- Profit margin of -150.0% highlights significant losses relative to revenue.
- Beta of 1.00 suggests market-average volatility compared to the overall market.
Strengths
- Innovative transdermal drug delivery technologies.
- Established manufacturing capabilities.
- Strategic partnerships with pharmaceutical companies.
- Focus on improving patient compliance and drug efficacy.
Weaknesses
- Negative profitability and high operating losses.
- Limited product portfolio compared to larger pharmaceutical companies.
- Dependence on partnerships for market access.
- High research and development costs.
Catalysts
- Upcoming: Potential regulatory approvals for new transdermal products.
- Ongoing: Expansion of existing partnerships with pharmaceutical companies.
- Ongoing: Development of advanced transdermal technologies.
Risks
- Potential: Competition from established pharmaceutical companies.
- Potential: Regulatory hurdles and delays in product approvals.
- Potential: Technological obsolescence.
- Ongoing: Negative profitability and high operating losses.
Growth Opportunities
- Expansion into New Therapeutic Areas: Corium has the opportunity to leverage its transdermal drug delivery technology to develop products for new therapeutic areas, such as central nervous system disorders and women's health. The market for transdermal drug delivery in these areas is estimated to reach $5 billion by 2030, offering significant growth potential. Successful expansion will depend on Corium's ability to identify unmet medical needs and develop innovative transdermal formulations.
- Strategic Partnerships and Collaborations: Corium can drive growth through strategic partnerships and collaborations with pharmaceutical companies and research institutions. By partnering with established players, Corium can gain access to new markets, technologies, and funding. The pharmaceutical industry is increasingly relying on collaborations to accelerate drug development and commercialization, creating opportunities for Corium to expand its reach and impact.
- Development of Advanced Transdermal Technologies: Corium can invest in the development of advanced transdermal technologies, such as micro-needle patches and enhanced permeation enhancers, to improve drug delivery efficiency and patient comfort. These technologies have the potential to revolutionize the transdermal drug delivery market, offering improved drug absorption and reduced skin irritation. The market for advanced transdermal technologies is projected to grow at a rate of 15% per year, providing a significant growth opportunity for Corium.
- Geographic Expansion: Corium can expand its geographic presence by entering new markets in Asia and Latin America. These regions offer significant growth potential due to their large populations and increasing healthcare spending. Successful geographic expansion will require Corium to adapt its products and marketing strategies to local market conditions and regulatory requirements.
- Acquisition of Complementary Technologies: Corium can pursue acquisitions of companies with complementary technologies or product portfolios to expand its capabilities and market share. This strategy can enable Corium to accelerate its growth and diversify its revenue streams. The pharmaceutical industry is undergoing consolidation, creating opportunities for Corium to acquire valuable assets and strengthen its competitive position.
Opportunities
- Expansion into new therapeutic areas.
- Development of advanced transdermal technologies.
- Geographic expansion into emerging markets.
- Acquisition of complementary technologies.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays in product approvals.
- Technological obsolescence.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary transdermal drug delivery technologies.
- Established manufacturing capabilities for transdermal products.
- Strong relationships with pharmaceutical partners.
- Intellectual property protection for key products and technologies.
About CORI
Corium International, Inc. is a biopharmaceutical company dedicated to the development, manufacture, and commercialization of innovative transdermal drug delivery systems. Founded with the goal of improving patient outcomes through advanced drug delivery technologies, Corium focuses on creating products that enhance drug efficacy, patient compliance, and overall treatment experience. The company's core expertise lies in its proprietary transdermal technology platforms, which enable the controlled release of drugs through the skin, offering an alternative to traditional oral or injectable medications. Corium's product portfolio includes prescription and over-the-counter transdermal products addressing a range of therapeutic areas, such as cardiovascular disease, pain management, and dermatology. The company's geographic reach extends across North America and Europe, with a focus on strategic partnerships and collaborations to expand its market presence. Corium's business model involves research and development, manufacturing, and commercialization of its transdermal products, with a focus on licensing and distribution agreements to maximize market access. The company faces competition from other pharmaceutical companies and drug delivery technology providers, requiring continuous innovation and strategic execution to maintain its competitive edge.
What They Do
- Develop transdermal drug delivery systems.
- Manufacture transdermal patches and related products.
- Commercialize transdermal products for various therapeutic areas.
- Research and develop new drug delivery technologies.
- Partner with pharmaceutical companies for product development and distribution.
- Seek regulatory approvals for new transdermal products.
Business Model
- Develop and patent transdermal drug delivery technologies.
- Manufacture transdermal products for own brands and partners.
- License technologies and products to other pharmaceutical companies.
- Generate revenue through product sales and licensing fees.
Industry Context
Corium International, Inc. operates within the pharmaceutical industry, specifically focusing on drug delivery technologies. The transdermal drug delivery market is driven by the increasing demand for non-invasive drug administration methods and improved patient compliance. The industry faces competition from established pharmaceutical companies and specialized drug delivery technology providers. Market trends include the development of advanced transdermal patches with enhanced drug delivery capabilities and the expansion of transdermal technology into new therapeutic areas. Corium's success depends on its ability to innovate, secure regulatory approvals, and establish strategic partnerships in a competitive landscape.
Key Customers
- Pharmaceutical companies seeking drug delivery solutions.
- Patients using transdermal products for various medical conditions.
- Healthcare providers prescribing transdermal medications.
- Distributors and wholesalers of pharmaceutical products.
Financials
Chart & Info
Corium International, Inc. (CORI) stock price: Price data unavailable
Latest News
No recent news available for CORI.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CORI.
Price Targets
Wall Street price target analysis for CORI.
MoonshotScore
What does this score mean?
The MoonshotScore rates CORI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Corium International, Inc. Stock: Key Questions Answered
What does Corium International, Inc. do?
Corium International, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing transdermal drug delivery systems. These systems deliver medication through the skin via a patch, offering an alternative to pills or injections. Corium partners with pharmaceutical companies to develop and market its products, aiming to improve patient compliance and drug efficacy. The company's business model centers on licensing its technology and selling its manufactured products to these partners.
What do analysts say about CORI stock?
AI analysis is pending for CORI, therefore analyst sentiment is unknown. Investors should monitor financial metrics such as revenue growth, gross margin, and profitability to assess the company's performance. Key considerations include the company's ability to secure regulatory approvals for new products, expand its partnerships, and manage its operating expenses. The company's negative P/E ratio and profit margin warrant careful evaluation.
What are the main risks for CORI?
Corium faces several risks, including competition from larger pharmaceutical companies with greater resources, regulatory hurdles in obtaining approvals for new products, and the potential for technological obsolescence. The company's financial performance is also a concern, given its negative profitability and high operating losses. Dependence on partnerships for market access and the need for significant investment in research and development also pose risks to Corium's future growth.
What are the key factors to evaluate for CORI?
Corium International, Inc. (CORI) currently holds an AI score of 44/100, indicating low score. Key strength: Innovative transdermal drug delivery technologies.. Primary risk to monitor: Potential: Competition from established pharmaceutical companies.. This is not financial advice.
How frequently does CORI data refresh on this page?
CORI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CORI's recent stock price performance?
Recent price movement in Corium International, Inc. (CORI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative transdermal drug delivery technologies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CORI overvalued or undervalued right now?
Determining whether Corium International, Inc. (CORI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CORI?
Before investing in Corium International, Inc. (CORI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available information.
- AI analysis is pending for CORI.
- The competitive landscape is subject to change.